Hansa Biopharma AB (publ) (HNSA.ST)
SEK 33.3
(17.42%)
SEK 33.3
(17.42%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 9.79 Million SEK | 906.37% |
| 2022 | 973 Thousand SEK | 302.07% |
| 2021 | 242 Thousand SEK | 146.94% |
| 2020 | 98 Thousand SEK | 9900.0% |
| 2019 | -1000.00 SEK | 99.99% |
| 2018 | -7.1 Million SEK | 8.93% |
| 2017 | -7.8 Million SEK | -183.88% |
| 2016 | -2.74 Million SEK | -274800100.0% |
| 2015 | 1.00 SEK | 100.0% |
| 2014 | -229 Thousand SEK | -22900100.0% |
| 2013 | 1.00 SEK | 0.0% |
| 2012 | 1.00 SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.2 Million SEK | -87.73% |
| 2024 Q2 | 2.11 Million SEK | 76.27% |
| 2024 Q3 | 1.97 Million SEK | -6.66% |
| 2023 FY | 9.79 Million SEK | 906.37% |
| 2023 Q4 | 9.79 Million SEK | 213.85% |
| 2023 Q2 | 2.5 Million SEK | 141.18% |
| 2023 Q1 | 1.03 Million SEK | 6.58% |
| 2023 Q3 | 3.12 Million SEK | 24.75% |
| 2022 FY | 973 Thousand SEK | 302.07% |
| 2022 Q3 | 957 Thousand SEK | 153.85% |
| 2022 Q1 | 184 Thousand SEK | -23.97% |
| 2022 Q2 | 377 Thousand SEK | 104.89% |
| 2022 Q4 | 973 Thousand SEK | 1.67% |
| 2021 Q1 | 83 Thousand SEK | -15.31% |
| 2021 FY | 242 Thousand SEK | 146.94% |
| 2021 Q3 | 123 Thousand SEK | 0.0% |
| 2021 Q4 | 242 Thousand SEK | 96.75% |
| 2021 Q2 | 123 Thousand SEK | 48.19% |
| 2020 Q4 | 98 Thousand SEK | 41104179199900.0% |
| 2020 Q3 | - SEK | 500.0% |
| 2020 FY | 98 Thousand SEK | 9900.0% |
| 2020 Q1 | -15.33 Million SEK | -2837.55% |
| 2020 Q2 | - SEK | 100.0% |
| 2019 Q2 | - SEK | 100.0% |
| 2019 Q4 | -522 Thousand SEK | 90.69% |
| 2019 Q3 | -5.6 Million SEK | -4703492505600100.0% |
| 2019 Q1 | -3.79 Million SEK | -6443.1% |
| 2019 FY | -1000.00 SEK | 99.99% |
| 2018 Q1 | -12.53 Million SEK | -2367.32% |
| 2018 Q2 | -9.31 Million SEK | 25.68% |
| 2018 Q4 | -58 Thousand SEK | 99.2% |
| 2018 Q3 | -7.25 Million SEK | 22.09% |
| 2018 FY | -7.1 Million SEK | 8.93% |
| 2017 Q4 | -508 Thousand SEK | -50799900.76% |
| 2017 Q1 | -3.24 Million SEK | -4286.49% |
| 2017 Q3 | -1.00 SEK | 100.0% |
| 2017 Q2 | -3.23 Million SEK | 0.43% |
| 2017 FY | -7.8 Million SEK | -183.88% |
| 2016 Q3 | -1.39 Million SEK | 27.15% |
| 2016 Q4 | -74 Thousand SEK | 94.68% |
| 2016 Q2 | -1.9 Million SEK | -14.25% |
| 2016 FY | -2.74 Million SEK | -274800100.0% |
| 2016 Q1 | -1.67 Million SEK | -167000100.0% |
| 2015 Q4 | 1.00 SEK | 100.0% |
| 2015 Q3 | -2.69 Million SEK | -9036208537600100.0% |
| 2015 Q2 | - SEK | 100.0% |
| 2015 Q1 | -179 Thousand SEK | 21.83% |
| 2015 FY | 1.00 SEK | 100.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q2 | -1.29 Million SEK | 0.0% |
| 2014 Q4 | -229 Thousand SEK | 0.0% |
| 2014 FY | -229 Thousand SEK | -22900100.0% |
| 2013 Q1 | - SEK | -100.0% |
| 2013 FY | 1.00 SEK | 0.0% |
| 2013 Q4 | 1.00 SEK | 0.0% |
| 2013 Q3 | 1.00 SEK | 53687091100.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 FY | 1.00 SEK | 0.0% |
| 2012 Q4 | 1.00 SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2009 Q2 | - SEK | 0.0% |
| 2009 Q4 | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 Q4 | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | -489599900.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 333.755% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 237.22% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 34.304% |
| Intervacc AB (publ) | 10.48 Million SEK | 6.592% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | 391780.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 72.205% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | -7.984% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 502253.846% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | -210.857% |
| Saniona AB (publ) | 1.00 SEK | -979199900.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 702.214% |
| Biovica International AB (publ) | 2.19 Million SEK | -345.293% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -979199900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | -370.769% |
| Xintela AB (publ) | 398 Thousand SEK | -2360.302% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -1298.857% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 1234.648% |
| Amniotics AB (publ) | 534 Thousand SEK | -1733.708% |
| 2cureX AB (publ) | -1000.00 SEK | 979300.0% |
| CombiGene AB (publ) | -1.79 Million SEK | 644.302% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 52.066% |
| Camurus AB (publ) | 100.95 Million SEK | 90.301% |
| Corline Biomedical AB | -3.85 Million SEK | 353.876% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -979100.0% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | 4.28 Million SEK | -128.785% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 298.661% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | -1695.916% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 77.634% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 2290.673% |
| Nanologica AB (publ) | 2.97 Million SEK | -229.364% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 3149.09% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 17.325% |
| Alzinova AB (publ) | -3.27 Million SEK | 398.719% |
| Oncopeptides AB (publ) | 2.42 Million SEK | -303.794% |
| Pila Pharma AB (publ) | 1.00 SEK | -979199900.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 659050.202% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | -142.737% |
| Simris Alg AB (publ) | 1.09 Million SEK | -797.525% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 59.285% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 90.836% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -852.529% |